NL8302569A - Pirprofen bevattend geneeskundig preparaat. - Google Patents

Pirprofen bevattend geneeskundig preparaat. Download PDF

Info

Publication number: NL8302569A
Authority: NL; Netherlands
Prior art keywords: pirprofen; cyclodextrin; mixture; inclusion compound; preparation according
Prior art date: 1982-07-19

Application number

NL8302569A

Other languages

English (en)

Dutch (nl)

Original Assignee

Ciba Geigy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-19

Filing date

1983-07-18

Publication date

1984-02-16

1983-07-18 Application filed by Ciba Geigy filed Critical Ciba Geigy

1984-02-16 Publication of NL8302569A publication Critical patent/NL8302569A/nl

Links

238000002360 preparation method Methods 0.000 title claims description 17
229920000858 Cyclodextrin Polymers 0.000 claims description 60
239000000203 mixture Substances 0.000 claims description 46
150000001875 compounds Chemical class 0.000 claims description 34
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 24
239000000126 substance Substances 0.000 claims description 17
-1 3-pyrrolin-1-yl Chemical group 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
229910019142 PO4 Inorganic materials 0.000 claims 1
208000002193 Pain Diseases 0.000 claims 1
208000025747 Rheumatic disease Diseases 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 1
201000003068 rheumatic fever Diseases 0.000 claims 1
PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 81
229960000851 pirprofen Drugs 0.000 description 81
239000001116 FEMA 4028 Substances 0.000 description 35
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 35
235000011175 beta-cyclodextrine Nutrition 0.000 description 35
229960004853 betadex Drugs 0.000 description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
239000000843 powder Substances 0.000 description 18
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
230000007794 irritation Effects 0.000 description 10
239000000725 suspension Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
239000000243 solution Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
235000019658 bitter taste Nutrition 0.000 description 6
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000006188 syrup Substances 0.000 description 6
235000020357 syrup Nutrition 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
229910000397 disodium phosphate Inorganic materials 0.000 description 5
235000019800 disodium phosphate Nutrition 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000001488 sodium phosphate Substances 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
239000000975 dye Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
229940083542 sodium Drugs 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
229940105329 carboxymethylcellulose Drugs 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000001341 hydroxy propyl starch Substances 0.000 description 3
235000013828 hydroxypropyl starch Nutrition 0.000 description 3
230000000622 irritating effect Effects 0.000 description 3
238000004898 kneading Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000004570 mortar (masonry) Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
229910052724 xenon Inorganic materials 0.000 description 3
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
238000004566 IR spectroscopy Methods 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
238000000862 absorption spectrum Methods 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
238000004042 decolorization Methods 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229960005141 piperazine Drugs 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000013112 stability test Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229910000406 trisodium phosphate Inorganic materials 0.000 description 2
235000019801 trisodium phosphate Nutrition 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000303040 Glycyrrhiza glabra Species 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
235000017443 Hedysarum boreale Nutrition 0.000 description 1
235000007858 Hedysarum occidentale Nutrition 0.000 description 1
244000267823 Hydrangea macrophylla Species 0.000 description 1
235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
235000019501 Lemon oil Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
235000010494 karaya gum Nutrition 0.000 description 1
239000000231 karaya gum Substances 0.000 description 1
229940039371 karaya gum Drugs 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000010501 lemon oil Substances 0.000 description 1
229960001078 lithium Drugs 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229960003506 piperazine hexahydrate Drugs 0.000 description 1
AVRVZRUEXIEGMP-UHFFFAOYSA-N piperazine;hexahydrate Chemical compound O.O.O.O.O.O.C1CNCCN1 AVRVZRUEXIEGMP-UHFFFAOYSA-N 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229960004109 potassium acetate Drugs 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229940093956 potassium carbonate Drugs 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
229940093932 potassium hydroxide Drugs 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000019640 taste Nutrition 0.000 description 1
230000009967 tasteless effect Effects 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
239000013638 trimer Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medical Informatics (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)

NL8302569A 1982-07-19 1983-07-18 Pirprofen bevattend geneeskundig preparaat. NL8302569A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP12555982		1982-07-19
JP57125559A JPS5920230A (ja)	1982-07-19	1982-07-19	ピルプロフエン含有薬剤

Publications (1)

Publication Number	Publication Date
NL8302569A true NL8302569A (nl)	1984-02-16

Family

ID=14913191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8302569A NL8302569A (nl)	1982-07-19	1983-07-18	Pirprofen bevattend geneeskundig preparaat.

Country Status (14)

Country	Link
US (1)	US4565807A (fr)
JP (1)	JPS5920230A (fr)
AU (1)	AU1695683A (fr)
BE (1)	BE897311A (fr)
CH (1)	CH655850A5 (fr)
DE (1)	DE3325615A1 (fr)
FR (1)	FR2530143B1 (fr)
GB (1)	GB2124489A (fr)
IT (1)	IT1197680B (fr)
LU (1)	LU84919A1 (fr)
NL (1)	NL8302569A (fr)
NZ (1)	NZ204929A (fr)
SE (1)	SE8304003L (fr)
ZA (1)	ZA835202B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1196033B (it) *	1984-02-22	1988-11-10	Chiesi Farma Spa	Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPH082186B2 (ja) *	1984-09-28	1996-01-10	キヤノン株式会社	振動波モータ
HU199444B (en) *	1985-09-10	1990-02-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
YU43290B (en) *	1986-11-13	1989-06-30	Lek Tovarna Farmacevtskih	Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
JPH0614849Y2 (ja) *	1987-06-03	1994-04-20	スタンレー電気株式会社	超音波振動発生部の支持構造
JPS63202189U (fr) *	1987-06-12	1988-12-27
IT1204725B (it) *	1987-06-17	1989-03-10	Edmond Pharma Srl	Complessi di inclusione del dipiridamolo con ciclodestrine
JPS6412493U (fr) *	1987-07-10	1989-01-23
US5017566A (en) *	1987-12-30	1991-05-21	University Of Florida	Redox systems for brain-targeted drug delivery
US5002935A (en) *	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
SI8810082A8 (en) *	1988-01-18	1995-12-31	Lek Tovarna Farmacevtskih	Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
DE3809808A1 (de) *	1988-03-23	1989-10-05	Hexal Pharma Gmbh & Co Kg	Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) *	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
FR2660309B1 (fr) *	1990-03-27	1992-07-17	Roussel Uclaf	Nouveaux complexes de l'acide tiaprofenique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs derives.
IT1241088B (it) *	1990-03-27	1993-12-29	Chiesi Farma Spa	Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US20040014695A1 (en) *	1992-06-19	2004-01-22	Supergen, Inc.	Pharmaceutical formulation
US5602112A (en) *	1992-06-19	1997-02-11	Supergen, Inc.	Pharmaceutical formulation
HU210922B (en) *	1993-05-24	1995-09-28	Europharmaceuticals Sa	Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
GB9316580D0 (en) *	1993-08-10	1993-09-29	Smithkline Beecham Plc	Pharmaceutical composition
JPH10500982A (ja) *	1994-05-27	1998-01-27	ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ	医薬組成物
ZA959469B (en) *	1994-11-15	1996-05-15	South African Druggists Ltd	Pharmaceutical composition
US6596263B1 (en)	1995-07-14	2003-07-22	Stc English Ideas, Inc.	Cyclodextrin compositions
US5824668A (en) *	1996-11-07	1998-10-20	Supergen, Inc.	Formulation for administration of steroid compounds
US5942501A (en) *	1996-08-16	1999-08-24	Collaborative Laboratories, Inc.	Cyclodextrin derivative complex
DE19758100B4 (de) *	1997-12-18	2006-05-04	Lichtwer Pharma Ag	Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
US7141555B2 (en)	2000-12-19	2006-11-28	Cephalon, Inc.	Modafinil compound and cyclodextrin mixtures
US7704975B2 (en) *	2000-12-19	2010-04-27	Cephalon, Inc.	Modafinil compound and cyclodextrin mixtures
EP1771161B1 (fr) *	2004-07-22	2010-04-21	Bend Research, Inc	Formulation de masquage du gout comprenant un medicament a dissolution retardee et/ou de la cyclodextrine a dissolution amelioree
US20070010487A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010466A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009532A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010486A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US8920918B2 (en) *	2005-10-31	2014-12-30	Kee Action Sports Technology Holdings, Llc	Oil and polyethylene glycol fill material for use in paintball shells
EP2238973A1 (fr)	2009-04-07	2010-10-13	Cephalon France	Préparations lyophilisées d'inhibiteurs du protéasome
ES2363964B1 (es)	2009-11-20	2012-08-22	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5423966B2 (fr) *	1972-11-11	1979-08-17
US4024223A (en) *	1972-11-11	1977-05-17	Teijin Limited	Stripe composition and method of reducing smell associated therewith
GB1497829A (en) *	1975-04-21	1978-01-12	May & Baker Ltd	11-deoxyprostaglandins
ZA762548B (en) *	1976-04-28	1977-04-27	Ono Pharmaceutical Co	New prostaglandin analogues
HU179141B (fr) *	1977-09-23	1982-08-28
HU176215B (en) *	1978-01-27	1981-01-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
HU176217B (en) *	1978-11-20	1981-01-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof
HU177081B (en) *	1978-12-12	1981-07-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing the occlusion complex of allicin with cyclodextrin
JPS5830032B2 (ja) *	1981-02-18	1983-06-27	呉羽化学工業株式会社	ビフイダス菌の増殖剤
JPS5813541A (ja) *	1981-07-16	1983-01-26	Kureha Chem Ind Co Ltd	エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
US4407795A (en) *	1981-07-16	1983-10-04	American Cyanamid Company	Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

1982
- 1982-07-19 JP JP57125559A patent/JPS5920230A/ja active Pending
1983
- 1983-07-11 US US06/512,793 patent/US4565807A/en not_active Expired - Fee Related
- 1983-07-12 CH CH3821/83A patent/CH655850A5/de not_active IP Right Cessation
- 1983-07-13 FR FR8311688A patent/FR2530143B1/fr not_active Expired
- 1983-07-15 SE SE8304003A patent/SE8304003L/xx not_active Application Discontinuation
- 1983-07-15 DE DE19833325615 patent/DE3325615A1/de not_active Withdrawn
- 1983-07-18 BE BE0/211189A patent/BE897311A/fr not_active IP Right Cessation
- 1983-07-18 NZ NZ204929A patent/NZ204929A/en unknown
- 1983-07-18 ZA ZA835202A patent/ZA835202B/xx unknown
- 1983-07-18 AU AU16956/83A patent/AU1695683A/en not_active Abandoned
- 1983-07-18 NL NL8302569A patent/NL8302569A/nl not_active Application Discontinuation
- 1983-07-18 LU LU84919A patent/LU84919A1/de unknown
- 1983-07-18 IT IT48702/83A patent/IT1197680B/it active
- 1983-07-19 GB GB08319407A patent/GB2124489A/en not_active Withdrawn

Also Published As

Publication number	Publication date
FR2530143A1 (fr)	1984-01-20
FR2530143B1 (fr)	1986-04-18
AU1695683A (en)	1984-01-26
BE897311A (fr)	1984-01-18
IT8348702A0 (it)	1983-07-18
JPS5920230A (ja)	1984-02-01
CH655850A5 (de)	1986-05-30
NZ204929A (en)	1986-05-09
SE8304003D0 (sv)	1983-07-15
IT1197680B (it)	1988-12-06
DE3325615A1 (de)	1984-02-16
SE8304003L (sv)	1984-01-20
GB8319407D0 (en)	1983-08-17
LU84919A1 (de)	1984-03-22
ZA835202B (en)	1984-03-28
US4565807A (en)	1986-01-21
GB2124489A (en)	1984-02-22

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1987-03-02	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8302569A (nl)	1984-02-16	Pirprofen bevattend geneeskundig preparaat.
EP0346006B1 (fr)	1992-12-30	Compositions pharmaceutiques contenant des complexes de cyclodextrine et d'ibuprofène
US5512306A (en)	1996-04-30	Smoking substitute
KR870001960B1 (ko)	1987-10-23	피록시캄 착물의 제조 방법
HU227798B1 (en)	2012-03-28	Pharmaceutical composition stabilized with a basic agent
NL8701507A (nl)	1988-02-01	Kristallijn hydraat van oraal cefalosporine en geneesmiddel daaruit.
HU183430B (en)	1984-05-28	Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
AU675146B2 (en)	1997-01-23	New nimesulide salt cyclodextrin inclusion complexes
WO1994028031A9 (fr)	1995-03-23	Nouveaux complexes d'insertion de sels de nimesulide et de cyclodextrine
Sharapova et al.	2024	Integrative approach for improved dofetilide solubility using β-cyclodextrin and two its substituted derivatives: solutions and solid dispersions
JPH0332524B2 (fr)	1991-05-13
RU2111216C1 (ru)	1998-05-20	Комплекс включения n-этоксикарбонил-3-морфолинсиднонимина или его соли с циклодекстрином или производным циклодекстрина, способ получения этого комплекса включения, фармацевтические композиции и способ их получения, способ лечения
US4925931A (en)	1990-05-15	N-homocysteine thiolactonyl retinamido cobalamin and methods of use thereof
JP7823968B2 (ja)	2026-03-04	日焼け止め化粧料用テレフタリリデンジカンファースルホン酸の有機塩及びその製造方法
KR100759159B1 (ko)	2007-09-14	파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
JPH04506221A (ja)	1992-10-29	３―モルホリノ―シドノンイミン又はその塩又はその互変異性体の包接錯体、その製法、及び該包接錯体を含有する医薬組成物
KR960004018B1 (ko)	1996-03-25	L-글루타민과 수용성아줄렌 복합 항궤양용 제제의 안정화 방법
JPH0322874B2 (fr)	1991-03-27
CN100415756C (zh)	2008-09-03	草酸阿地福韦酯及其晶型和制备方法及用途
SA90100090B1 (ar)	2004-03-31	أملاح الرانيتدين ومعقدات البزموت مع الحموض الكربوكسيلية وتراكيبهما الصيدلية
JPS6054304B2 (ja)	1985-11-29	ジソピラミド包接化合物
JPS61293912A (ja)	1986-12-24	配合剤及びその製造法
NL8204951A (nl)	1983-07-18	Gamma-kristallen van bestatine en werkwijze ter bereiding daarvan.
JPS6341374B2 (fr)	1988-08-17
JP2003095939A (ja)	2003-04-03	安定なプラバスタチンナトリウム錠